Cash flow Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 10/04/2026 BST			5-day change	1st Jan Change
322.11 ^USD	+0.26%		+1.02%	-19.00%

04-06	BioCryst Pharmaceuticals, Inc. Appoints Sandeep M. Menon As Chief Research And Development Officer	CI
03-30	Alnylam Pharmaceuticals Announces New Data Supporting Benefits of Vutrisiran in Attr-Cm and Potential of Zilebesiran for Hypertension Management	CI

df2e7fe7a8554.DOWcnY7pid2Pz3T2xvJxyVDXG6WeN1t4zOCzMR4kqsM.dr_l2P2KupvF_jjbo5pChGChfc30bQwTi4TZCF117IZDoNbS4K67pL2HQA

Published financial data: ALNYLAM PHARMACEUTICALS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	844M	1.04B	1.83B	2.25B	3.71B
Total Revenues	844M	1.04B	1.83B	2.25B	3.71B
Cost of Goods Sold, Total	140M	169M	310M	323M	682M
Gross Profit	704M	869M	1.52B	1.92B	3.03B
Selling General & Admin Expenses, Total	702M	771M	796M	976M	1.21B
R&D Expenses	711M	883M	1B	1.13B	1.32B
Other Operating Expenses, Total	1.41B	1.65B	1.8B	2.1B	2.53B
Operating Income	-709M	-785M	-282M	-177M	502M
Interest Expense, Total	-143M	-156M	-121M	-142M	-253M
Interest And Investment Income	1.58M	24.81M	95.56M	122M	111M
Net Interest Expenses	-141M	-131M	-25.66M	-19.87M	-141M
Other Non Operating Income (Expenses)	-57.74M	-101M	-109M	-178M	-34.96M
EBT, Excl. Unusual Items	-908M	-1.02B	-417M	-374M	325M
Gain (Loss) On Sale Of Investments	55.7M	-33.31M	-16.94M	-3.02M	-2.31M
Legal Settlements	-	-	-	-	-
Other Unusual Items	-	-76.59M	-	-	-
EBT, Incl. Unusual Items	-852M	-1.13B	-434M	-377M	323M
Income Tax Expense	680K	4.16M	6.72M	-99.22M	9.4M
Earnings From Continuing Operations	-853M	-1.13B	-440M	-278M	314M
Net Income to Company	-853M	-1.13B	-440M	-278M	314M
Net Income - (IS)	-853M	-1.13B	-440M	-278M	314M
Net Income to Common Incl Extra Items	-853M	-1.13B	-440M	-278M	314M
Net Income to Common Excl. Extra Items	-853M	-1.13B	-440M	-278M	314M
Per Share Items
Net EPS - Basic	-7.2	-9.3	-3.52	-2.18	2.39
Basic EPS - Continuing Operations	-7.2	-9.3	-3.52	-2.18	2.39
Basic Weighted Average Shares Outstanding	118M	122M	125M	128M	131M
Net EPS - Diluted	-7.2	-9.3	-3.52	-2.18	2.33
Diluted EPS - Continuing Operations	-7.2	-9.3	-3.52	-2.18	2.33
Diluted Weighted Average Shares Outstanding	118M	122M	125M	128M	135M
Normalized Basic EPS	-4.79	-5.22	-2.08	-1.83	1.55
Normalized Diluted EPS	-4.79	-5.22	-2.08	-1.83	1.51
American Depositary Receipts Ratio (ADR)	0.05	0.05	0.05	0.05	0.05
Supplemental Items
EBITDA	-661M	-741M	-228M	-120M	557M
EBITA	-709M	-785M	-282M	-177M	502M
EBIT	-709M	-785M	-282M	-177M	502M
EBITDAR	-535M	-723M	-161M	-54.47M	632M
Total Revenues (As Reported)	844M	1.04B	1.83B	2.25B	3.71B
Effective Tax Rate - (Ratio)	-0.08	-0.37	-1.55	26.29	2.91
Current Domestic Taxes	293K	-	4.02M	1.6M	1.93M
Current Foreign Taxes	3.15M	5.6M	3.42M	5.94M	9.67M
Total Current Taxes	3.45M	5.6M	7.44M	7.54M	11.6M
Deferred Domestic Taxes	-	-	-	-	-
Deferred Foreign Taxes	-2.77M	-1.43M	-713K	-107M	-2.2M
Total Deferred Taxes	-2.77M	-1.43M	-713K	-107M	-2.2M
Normalized Net Income	-567M	-636M	-260M	-234M	203M
Interest on Long-Term Debt	143M	48.37M	14.67M	142M	253M
Supplemental Operating Expense Items
Advertising Expense	-	-	-	29.7M	36M
General and Administrative Expenses	-	-	-	-	-
Research And Development Expense From Footnotes	792M	883M	1B	1.13B	1.32B
Net Rental Expense, Total	126M	17.61M	66.64M	65.74M	74.37M
Imputed Operating Lease Interest Expense	76.45M	9.16M	24.41M	27.5M	52.62M
Imputed Operating Lease Depreciation	49.78M	8.45M	42.23M	38.24M	21.74M
Stock-Based Comp., R&D Exp. (Total)	68.42M	92.16M	97.27M	128M	153M
Stock-Based Comp., G&A Exp. (Total)	-	-	-	-	-
Stock-Based Comp., SG&A Exp. (Total)	97.3M	138M	124M	144M	195M
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	166M	231M	222M	272M	348M

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	820M	866M	813M	966M	1.66B
Short Term Investments	1.62B	1.33B	1.63B	1.73B	1.25B
Total Cash And Short Term Investments	2.44B	2.19B	2.44B	2.69B	2.91B
Accounts Receivable, Total	199M	238M	328M	405M	778M
Other Receivables	-	-	-	-	-
Total Receivables	199M	238M	328M	405M	778M
Inventory	86.36M	129M	89.15M	78.51M	82.72M
Prepaid Expenses	88.08M	133M	126M	117M	282M
Restricted Cash	-	-	-	-	-
Total Current Assets	2.81B	2.69B	2.98B	3.3B	4.05B
Gross Property Plant And Equipment	874M	912M	949M	964M	1.03B
Accumulated Depreciation	-140M	-173M	-223M	-270M	-323M
Net Property Plant And Equipment	734M	739M	726M	694M	708M
Long-term Investments	-	-	-	-	-
Deferred Tax Assets Long-Term	-	-	-	117M	126M
Other Long-Term Assets, Total	101M	115M	121M	134M	81.63M
Total Assets	3.64B	3.55B	3.83B	4.24B	4.97B
Liabilities
Accounts Payable, Total	73.43M	98.09M	55.52M	88.42M	116M
Accrued Expenses, Total	372M	514M	655M	795M	821M
Current Portion of Long-Term Debt	37.08M	40.29M	54.99M	113M	220M
Current Portion of Leases	40.55M	41.97M	41.51M	41.89M	45.52M
Unearned Revenue Current, Total	149M	42.1M	103M	55.48M	4.84M
Other Current Liabilities	22.84M	31.68M	58.28M	92.31M	259M
Total Current Liabilities	696M	768M	968M	1.19B	1.47B
Long-Term Debt	1.83B	2.27B	2.34B	2.36B	2.48B
Long-Term Leases	281M	261M	243M	230M	225M
Unearned Revenue Non Current	152M	194M	188M	-	-
Pension & Other Post Retirement Benefits	4.3M	-	-	-	-
Other Non Current Liabilities	94.66M	213M	308M	398M	7.59M
Total Liabilities	3.06B	3.7B	4.05B	4.17B	4.18B
Common Stock, Total	1.2M	1.24M	1.26M	1.29M	1.32M
Additional Paid In Capital	6.06B	6.45B	6.81B	7.39B	7.51B
Retained Earnings	-5.44B	-6.57B	-7.01B	-7.29B	-6.7B
Comprehensive Income and Other	-33.26M	-44.65M	-23.38M	-34.52M	-20.1M
Total Common Equity	588M	-158M	-221M	67.09M	789M
Total Equity	588M	-158M	-221M	67.09M	789M
Total Liabilities And Equity	3.64B	3.55B	3.83B	4.24B	4.97B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	120M	124M	126M	129M	133M
ECS Total Common Shares Outstanding	120M	124M	126M	129M	132M
Book Value / Share	4.89	-1.28	-1.75	0.52	5.96
Tangible Book Value	588M	-158M	-221M	67.09M	789M
Tangible Book Value Per Share	4.89	-1.28	-1.75	0.52	5.96
Total Debt	2.19B	2.61B	2.68B	2.74B	2.97B
Net Debt	-250M	420M	243M	48.92M	60.31M
Debt Equivalent of Unfunded Proj. Benefit Obligation	4.3M	-	-	-	-
Debt Equivalent Oper. Leases	1.01B	141M	533M	526M	595M
Account Code - Inventory Valuation	5	5	5	5	5
Inventories - Raw Materials, Total	-	-	-	-	-
Inventories - Work In Process, Total	-	-	-	-	-
Inventories - Finished Goods, Total	-	-	-	-	-
Land - (BS)	9.08M	9.08M	9.08M	9.08M	9.08M
Buildings, Total	263M	269M	272M	295M	298M
Machinery, Total	138M	173M	203M	225M	247M
Full Time Employees	1.66K	2K	2.1K	2.23K	2.5K

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	-853M	-1.13B	-440M	-278M	314M
Depreciation & Amortization - CF	89.69M	85.55M	97.03M	56.67M	55.66M
Depreciation & Amortization, Total	89.69M	85.55M	97.03M	56.67M	55.66M
(Gain) Loss on Sale of Investments - (CF)	-55.7M	33.31M	16.94M	3.02M	2.31M
Stock-Based Compensation (CF)	166M	231M	222M	272M	348M
Other Operating Activities, Total	174M	276M	198M	152M	249M
Change In Accounts Receivable	-102M	-45.6M	-87.94M	-86.55M	-360M
Change In Inventories	-26.42M	-34.14M	18.37M	13.59M	8.47M
Change In Accounts Payable	88.24M	192M	80.84M	91.09M	75.07M
Change in Unearned Revenues	-50.4M	-65.91M	55.02M	-235M	-50.64M
Change in Other Net Operating Assets	-72.44M	-81.68M	-55.53M	3.23M	-118M
Cash from Operations	-642M	-541M	104M	-8.31M	524M
Capital Expenditure	-76.37M	-72.06M	-62.21M	-34.28M	-58.7M
Investment in Marketable and Equity Securities, Total	-193M	255M	-270M	-63.25M	497M
Other Investing Activities, Total	-4.36M	-13.19M	-4.44M	-19.32M	-2.15M
Cash from Investing	-273M	169M	-336M	-117M	436M
Long-Term Debt Issued, Total	500M	1.02B	-	-	646M
Total Debt Issued	500M	1.02B	-	-	646M
Long-Term Debt Repaid, Total	-	-881M	-	-	-1.19B
Total Debt Repaid	-	-881M	-	-	-1.19B
Issuance of Common Stock	246M	259M	147M	303M	250M
Repurchase of Common Stock	-	-	-	-	-
Other Financing Activities, Total	501M	31M	24.67M	-8.79M	-8.27M
Cash from Financing	1.25B	426M	172M	294M	-305M
Foreign Exchange Rate Adjustments	-9.02M	-7.43M	6.39M	-15.24M	34.94M
Net Change in Cash	323M	46.4M	-53.67M	154M	690M
Supplemental Items
Cash Interest Paid	24.66M	45.24M	32.12M	67.58M	219M
Cash Income Tax Paid (Refund)	-	-	-	14.36M	21.2M
Levered Free Cash Flow	97.11M	-403M	147M	198M	129M
Unlevered Free Cash Flow	187M	-306M	222M	287M	287M
Change In Net Working Capital	-450M	59.25M	-142M	-103M	372M
Net Debt Issued / Repaid	500M	135M	-	-	-547M

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	-12.56	-13.65	-4.78	-2.74	6.81
Return on Total Capital	-16.46	-18.77	-7.17	-4.19	9.55
Return On Equity %	-106.31	-526.14	232.4	362.29	73.28
Return on Common Equity	-106.31	-526.14	232.4	362.29	73.28
Margin Analysis
Gross Profit Margin %	83.4	83.73	83.02	85.62	81.64
SG&A Margin	83.16	74.29	43.52	43.39	32.6
EBITDA Margin %	-78.3	-71.39	-12.48	-5.35	15
EBITA Margin %	-83.93	-75.68	-15.43	-7.87	13.51
EBIT Margin %	-83.93	-75.68	-15.43	-7.87	13.51
Income From Continuing Operations Margin %	-101.01	-109.04	-24.08	-12.37	8.45
Net Income Margin %	-101.01	-109.04	-24.08	-12.37	8.45
Net Avail. For Common Margin %	-101.01	-109.04	-24.08	-12.37	8.45
Normalized Net Income Margin	-67.2	-61.28	-14.24	-10.41	5.48
Levered Free Cash Flow Margin	11.5	-38.87	8.01	8.8	3.47
Unlevered Free Cash Flow Margin	22.09	-29.48	12.16	12.75	7.72
Asset Turnover
Asset Turnover	0.24	0.29	0.5	0.56	0.81
Fixed Assets Turnover	1.17	1.41	2.5	3.17	5.3
Receivables Turnover (Average Receivables)	5.61	4.75	6.46	6.13	6.28
Inventory Turnover (Average Inventory)	1.73	1.57	2.85	3.86	8.46
Short Term Liquidity
Current Ratio	4.04	3.51	3.08	2.78	2.76
Quick Ratio	3.79	3.16	2.86	2.61	2.51
Operating Cash Flow to Current Liabilities	-0.92	-0.7	0.11	-0.01	0.36
Days Sales Outstanding (Average Receivables)	65.06	76.79	56.47	59.67	58.13
Days Outstanding Inventory (Average Inventory)	210.39	232.78	128.23	94.88	43.15
Average Days Payable Outstanding	151.24	148.06	103.6	84.22	54.3
Cash Conversion Cycle (Average Days)	124.21	161.51	81.1	70.33	46.98
Long Term Solvency
Total Debt/Equity	371.59	-1.65K	-1.22K	4.09K	376.19
Total Debt / Total Capital	78.8	106.45	108.96	97.61	79
LT Debt/Equity	358.39	-1.6K	-1.17K	3.86K	342.54
Long-Term Debt / Total Capital	76	103.1	105.04	92.1	71.93
Total Liabilities / Total Assets	83.86	104.46	105.76	98.42	84.11
EBIT / Interest Expense	-4.95	-5.03	-2.33	-1.25	1.99
EBITDA / Interest Expense	-3.74	-4.64	-1.33	-0.38	2.5
(EBITDA - Capex) / Interest Expense	-4.27	-5.1	-1.85	-0.63	2.27
Total Debt / EBITDA	-4.09	-3.61	-16.61	-50.36	4.7
Net Debt / EBITDA	0.47	-0.58	-1.51	-0.9	0.1
Total Debt / (EBITDA - Capex)	-3.58	-3.29	-11.99	-30.91	5.18
Net Debt / (EBITDA - Capex)	0.41	-0.53	-1.09	-0.55	0.11
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	71.31	22.88	76.23	22.97	65.19
Gross Profit, 1 Yr. Growth %	69.75	23.36	74.75	26.81	57.52
EBITDA, 1 Yr. Growth %	-16.7	12.03	-69.2	-47.3	-563.53
EBITA, 1 Yr. Growth %	-14.46	10.78	-64.06	-37.31	-383.56
EBIT, 1 Yr. Growth %	-14.46	10.78	-64.06	-37.31	-383.56
Earnings From Cont. Operations, 1 Yr. Growth %	-0.64	32.64	-61.08	-36.82	-212.79
Net Income, 1 Yr. Growth %	-0.64	32.64	-61.08	-36.82	-212.79
Normalized Net Income, 1 Yr. Growth %	-0.2	12.03	-59.04	-10.14	-186.94
Diluted EPS Before Extra, 1 Yr. Growth %	-3.54	29.11	-62.1	-38.18	-206.88
Accounts Receivable, 1 Yr. Growth %	93.89	19.84	37.75	23.65	91.85
Inventory, 1 Yr. Growth %	14.84	49.33	-30.87	-11.93	5.36
Net Property, Plant and Equip., 1 Yr. Growth %	3.84	0.68	-1.74	-4.39	2.04
Total Assets, 1 Yr. Growth %	6.93	-2.66	7.99	10.71	17.13
Tangible Book Value, 1 Yr. Growth %	-42.12	-126.9	39.45	-130.41	1.08K
Common Equity, 1 Yr. Growth %	-42.12	-126.9	39.45	-130.41	1.08K
Cash From Operations, 1 Yr. Growth %	4.35	-15.65	-119.24	-107.98	-6.41K
Capital Expenditures, 1 Yr. Growth %	8.54	-5.65	-13.67	-44.9	71.24
Levered Free Cash Flow, 1 Yr. Growth %	-112.5	-515.25	-136.34	91.09	-34.92
Unlevered Free Cash Flow, 1 Yr. Growth %	-125.75	-263.96	-172.7	59.8	0.05
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	96.01	45.08	47.16	47.21	42.53
Gross Profit, 2 Yr. CAGR %	90.18	44.71	46.82	48.86	41.34
EBITDA, 2 Yr. CAGR %	-15.34	-3.4	-41.26	-59.71	56.29
EBITA, 2 Yr. CAGR %	-13.15	-2.65	-36.9	-52.53	33.32
EBIT, 2 Yr. CAGR %	-13.15	-2.65	-36.9	-52.53	33.32
Earnings From Cont. Operations, 2 Yr. CAGR %	-1.9	14.8	-28.15	-50.41	-15.58
Net Income, 2 Yr. CAGR %	-1.9	14.8	-28.15	-50.41	-15.58
Normalized Net Income, 2 Yr. CAGR %	0.63	5.74	-32.26	-39.33	-11.61
Diluted EPS Before Extra, 2 Yr. CAGR %	-5.78	11.59	-30.03	-51.58	-18.69
Accounts Receivable, 2 Yr. CAGR %	114.87	52.43	28.48	30.51	54.02
Inventory, 2 Yr. CAGR %	23.8	30.95	1.6	-21.98	-3.67
Net Property, Plant and Equip., 2 Yr. CAGR %	6.54	2.25	-0.54	-3.07	-1.23
Total Assets, 2 Yr. CAGR %	23.33	2.02	2.53	9.34	13.87
Tangible Book Value, 2 Yr. CAGR %	-36.06	-60.54	-38.75	-34.88	89.12
Common Equity, 2 Yr. CAGR %	-36.06	-60.54	-38.75	-34.88	89.12
Cash From Operations, 2 Yr. CAGR %	51.81	-6.18	-59.71	-87.61	124.31
Capital Expenditures, 2 Yr. CAGR %	-26.18	1.2	-9.75	-31.03	-2.87
Levered Free Cash Flow, 2 Yr. CAGR %	-51.67	-27.96	22.83	-33.27	11.52
Unlevered Free Cash Flow, 2 Yr. CAGR %	-33.03	-35.03	9.17	-9.11	26.44
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	124.21	67.75	54.8	38.61	52.98
Gross Profit, 3 Yr. CAGR %	112.77	64.62	54.1	39.82	51.7
EBITDA, 3 Yr. CAGR %	-6.14	-7.05	-34.01	-43.35	-9.05
EBITA, 3 Yr. CAGR %	-4.54	-5.81	-30.16	-37.04	-13.87
EBIT, 3 Yr. CAGR %	-4.54	-5.81	-30.16	-37.04	-13.87
Earnings From Cont. Operations, 3 Yr. CAGR %	3.85	8.48	-19.95	-31.16	-34.78
Net Income, 3 Yr. CAGR %	3.85	8.48	-19.95	-31.16	-34.78
Normalized Net Income, 3 Yr. CAGR %	5.91	4.3	-22.92	-25.57	-31.6
Diluted EPS Before Extra, 3 Yr. CAGR %	-1.66	4.65	-22.13	-32.86	-36.95
Accounts Receivable, 3 Yr. CAGR %	119.56	76.87	47.37	26.85	48.39
Inventory, 3 Yr. CAGR %	53.1	31.78	5.83	-3.13	-13.76
Net Property, Plant and Equip., 3 Yr. CAGR %	31.77	4.55	0.9	-1.84	-1.4
Total Assets, 3 Yr. CAGR %	32.26	13.98	3.98	5.19	11.88
Tangible Book Value, 3 Yr. CAGR %	-23.27	-52.09	-39.9	-51.5	70.86
Common Equity, 3 Yr. CAGR %	-23.27	-52.09	-39.9	-51.5	70.86
Cash From Operations, 3 Yr. CAGR %	4.48	24.81	-44.67	-76.52	-1.07
Capital Expenditures, 3 Yr. CAGR %	-15.57	-19.89	-4.02	-23.44	-6.61
Levered Free Cash Flow, 3 Yr. CAGR %	-40.89	-1.02	-42.66	26.78	-33.82
Unlevered Free Cash Flow, 3 Yr. CAGR %	-26.53	-9.74	-32.55	15.39	-6.15
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	78.07	63.09	89.45	59.21	49.77
Gross Profit, 5 Yr. CAGR %	71.72	57.4	83.42	58.13	48.86
EBITDA, 5 Yr. CAGR %	10.06	8.69	-22.18	-33.47	-6.83
EBITA, 5 Yr. CAGR %	10.79	9.44	-19.11	-28.39	-9.55
EBIT, 5 Yr. CAGR %	10.79	9.44	-19.11	-28.39	-9.55
Earnings From Cont. Operations, 5 Yr. CAGR %	15.77	18.17	-10.38	-20.68	-18.23
Net Income, 5 Yr. CAGR %	15.77	18.17	-10.38	-20.68	-18.23
Normalized Net Income, 5 Yr. CAGR %	16.83	15.77	-11.43	-16.03	-18.58
Diluted EPS Before Extra, 5 Yr. CAGR %	8.49	11.39	-14.18	-23.11	-20.77
Accounts Receivable, 5 Yr. CAGR %	53.46	47.57	77.2	56.62	49.99
Inventory, 5 Yr. CAGR %	-	-	29.94	6.86	1.92
Net Property, Plant and Equip., 5 Yr. CAGR %	44.97	32.35	17.75	1.43	0.04
Total Assets, 5 Yr. CAGR %	23.6	12.2	19.45	12.1	7.83
Tangible Book Value, 5 Yr. CAGR %	-8.56	-38.28	-29.88	-45.83	-4.93
Common Equity, 5 Yr. CAGR %	-8.56	-38.28	-29.88	-45.83	-4.93
Cash From Operations, 5 Yr. CAGR %	15.84	7.17	-28.63	-50.46	-3.15
Capital Expenditures, 5 Yr. CAGR %	3.42	-7.11	-13.29	-24.55	-3.56
Levered Free Cash Flow, 5 Yr. CAGR %	-12.41	4.18	-20.8	-13.8	-30.2
Unlevered Free Cash Flow, 5 Yr. CAGR %	-0.2	-1.43	-13.92	-7.18	-16.92